PD1-expressing CD8 T cells have been identified as key effector cells in response to PD(L)1 inhibition in several tumour types, including breast cancer18, lung cancer19 and melanoma20, where persistent exposure of CD8 T cells to tumour antigens will stimulate differentiation towards a dysfunctional, exhausted phenotype. This evidence concerns the gene CD274 and neoplasm.